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Thirty-ﬁve percent of survivors were transplanted with related
donor cells, 25% with unrelated donor cells, and 40 percent had an
autologous transplant. Age at time of transplant ranged from 6
months to 69 years. Median age was 42.
The year of the survivor’s most recent transplant ranged from
1981 to 2006 with a median of 2002. Sixty-three of the respondents
had two or more transplants.
Issues of concer, rating by frequency with which they were cited,
are shown in Table 1.
Psychological health of the survivor (71%), monitoring long-
term complications (70%), chronic GVHD (74% allogeneic relat-
ed-donor transplant, 81% allogeneic unrelated-donor transplant)
and fatigue (66%) were the top issues cited by survivors. Other
major concerns were cognitive problems (49%), psychological
health of the family (47%), educating local doctors about long-
term follow-up care (43%), health insurance (42%), secondary
cancers (42%) and sexuality (41%).
Spouses expressed greater concern than survivors about ﬁnancial
problems (43% vs. 30%), psychological health of the family (59% vs.
47%), and caregiver burnout (44% vs. 29%). Survivors had greater
concern than spouses about cognitive problems (49% vs. 37%), sec-
ondary cancers (42% vs. 24%) and infertility (22% vs. 8%).
Spouses of survivors who were transplanted with unrelated donor
cells expressed concern more frequently than other spouses about
the psychological health of the survivor, fatigue, psychological
health of the family, and marital difﬁculties.
Ninety-one percent of respondents said they would be interested
in an educational forum to help them cope with survivorship issues.
The growing number of HSCT survivors requires a fresh look at
how to equip patients and families to live well post-transplant. The
results of this survey have been used to design of a one-day
Transplant Survivors Symposium, April 14, 2007 in Chicago IL.
Between 200 and 300 survivors and their families are expected to
attend. Symposium proceedings will be available to non-partici-
pants via the web, on CD, and in print.
Issues of Concern to HSCT Survivors and Spouses
Issue Survivors Spouses
Psychological Health of Survivor 71% 78%
Monitoring Long Term
Complications 70% 67%
Fatigue 66% 70%
Cognitive Problems 49% 37%
cGVHD 47% 49%
Psychological Health of Family 47% 59%
Educating Local Physicians About
Survivor Needs 43% 37%
Health Insurance 42% 44%
Secondary Cancers 42% 24%
Sexuality 41% 37%
Employment 36% 35%
Immunization 36% 30%
Life Insurance 33% 32%
Financial Problems 30% 43%
Caregiver Burnout 29% 44%
Dental Problems 26% 21%
Resume Relations w/ Family &
Friends 24% 17%
Infertility 22% 8%
Complementary/Alternative
Medicine 20% 13%
Marital Difficulties 20% 25%
Pain Control 19% 24%
Young Adult Issues 7% 5%
Sibling Needs 5% 3%
Behavioral Problems 2% 3%
Delayed Growth 1% 2%
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P53 MUTATIONS IN SECONDARY MALIGNANCIES AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Zouvelou, C.2, Bertz, H.2, Faber, P.2, Finke, J.2, Spyridonidis, A.1
1Hematology,Patras University Medical Center, Rio-Patras, Greece;
2Hematology-Oncology, Freiburg University Medical Center, Freiburg,
Germany.
We previously demonstrated frequent genomic alterations
measured by microsatellite instability (MSI) in non-malignant
and malignant epithelial tissues of pts who underwent aHCT
(Blood 2006;107:3389-3396). Transplant survivors have a high
risk of developing secondary cancer, especially squamous cell
carcinomas. The p53 gene plays a pivotal role in maintaining
genome integrity and in the development of cancer. We hy-
pothesized that besides the alterations in microsatellite regions
also p53 mutations occur after aHCT and may play a role in
malignant transformation and development of secondary cancer.
Therefore, we performed mutation analysis of the p53 gene on
malignant cells isolated from parafﬁn-embedded tumor biopsies
from 4 pts that developed secondary epithelial malignancies
2-12 years post aHCT and on non-neoplastic buccal cells ob-
tained from 4 otherwise healthy pts 3-5 years following aHCT.
Buccal cells from 3 healthy individuals and HaCat cells with a
known p53 heterozygous mutation were used as negative and
positive controls, respectively. DNA extraction was followed by
proofread-PCR with speciﬁc primers for the exons 5-8. Each
PCR product was cloned in a pUC vector and transfected in
Escherischia coli chemocompetent cells. Sequence analysis was
performed on 8-12 clones per exon per patient. p53 mutations
were not found in the buccal cells of the aHCT healthy recip-
ients. p53 mutations were evident in 2 out of 4 tumor specimens.
One patient with a squamous cell carcinoma developed 2 years
post aHCT was found to harbour a single p53 mutation in exon
8. This p53 mutation was evident in 10 out of the 10 clones
tested, suggesting that 100% of the malignant cells were mu-
tated. In the second patient with an underlying malignancy of
the tongue, two different mutations (exons 5 and 8) in 50% of
the isolated cells were detected. Despite the small size of the
sample (4 pts), p53 mutations seem to occur frequently (50%) in
secondary malignancies after HCT. We didn
t ﬁnd p53 muta-
tions in nonmalignant epithelial cells of the oral cavity. How-
ever, given the low sensitivity of the applied methodology (de-
tection of a mutation if it affects more than 40% of the tissue
cells) we cannot exclude that indeed p53 mutations are already
present in a lower percentage of non-neoplastic cells before
overt malignant transformation occurs. Results regarding the
presence of p53 mutations in nonmalignant tissues affected with
chronic GvHD will be presented in the meeting.
LYMPHOMA/MULTIPLE MYELOMA
142
LOW DOSE THALIDOMIDE MAINTENANCE IN MYELOMA PATIENTS
AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Bayer, R.-L.1, John, V.1, Devoe, C.1, Cannon, M.1, Klocke, J.1,
Gissinger, D.1 1North Shore University Hospital, Manhasset, NY.
Autologous stem cell transplantation has become the gold
standard for treatment of patients with multiple myeloma under
the age of 65, and improves survival for these patients. It is
evident that all patients will progress after transplantation. At
this time it is not clear what is the best induction regimen prior
to high dose chemotherapy and ASCT. Thalidomide has been
proven to impact on plasma cell growth through multiple mech-
anisms. At our institution we used thalidomide (50-100 mg)
after ASCT as a maintenance program along with a bisphos-
phonate (Zometa or Aredia). We reviewed 68 myeloma patients
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who were transplanted at our facility between 2001 and 2005. 30
patients were placed on a thalidomide maintenance program.
Patients received various cytoreductive regimens prior to stem-
cell collection. 27 patients who received thalidomide were in
partial remission prior to ASCT; 3 patients were in complete
remission and none were refractory. Of the 38 patients who did
not receive maintenance 35 were in partial remission, 2 were in
complete remission and 1 was refractory. All patients except 2
received a preparative regimen including melphalan 200 mg per
meter squared. 24 patients received thalidomide maintenance
with 100 mg daily and 6 patients received 50 mg daily. The dose
given depended on prior tolerability of the drug and history.
Thalidomide was started between 120 and 150 days post ASCT.
Patients needed to have an ANC above 1000 and platelets above
100 as well as resolution of transplant related toxicities. 13
patients needed a decrease in thalidomide because of neuropa-
thy. One of these 13 patients also suffered from decreased GI
motility and bezoar.
The average time to progression was 32.5 months in the thalid-
omide group and 19 months in the patients who did not receive the
drug. Patients who received thalidomide after transplant had im-
proved median time to progression (36 months) compared to
patients who did not receive thalidomide (15 months). Low dose
thalidomide maintenance in combination with bisphosphonates
seemed to improve progression free survival in myeloma patients
after stem cell transplantation.
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COMPARISON OF MULTIPLE MYELOMA PATIENTS TREATED WITH AU-
TOLOGOUS STEM CELL TRANSPLANT HAVING RECEIVED THAL DEX OR
VAD
Beveridge, C.A.1, Orloff, G.J.1, Sheridan, M.J.2, Shelton, M.V.1 1Fair-
fax Northern Virginia Hematology-Oncology, PC, Fairfax, VA; 2Inova
Fairfax Hospital, Falls Church, VA.
Background and Rationale
Thalidomide Dexamethasone (Thal Dex) is one of the standard
preparation treatments for auto-transplant in patients with Multi-
ple Myeloma (MM). We evaluated 49 patients with MM to deter-
mine whether outcomes differed between those receiving Thal Dex
and those receiving Vincristine, Doxorubicin, and Dexamethasone
(VAD).
Materials and Methods
A retrospective assessment was performed of MM patients who
were transplanted at Inova Fairfax Hospital from 1997-2005. All
patients received either VAD or Thal Dex as primary therapy and
in preparation for auto-transplant. All patients had Karnofsky per-
formance scores of 80% and all were apheresed using a high
volume technique and ideal body weight for calculations with
G-CSF (G) or GGM-CSF, with goal of 5106/kg CD34 cells. All
patients were given 200 mg/m2 of Melphalan (MEL) over two days
and were treated with growth factor support G beginning day 4
though ANC recovery of 1000. Blood product replacement was
standardized to transfuse for hemoglobin 8 gm/dl or platelet
counts of 10,000/mm3. Viability was performed using ﬂow cy-
tometry and propidium iodide. Continuous variables were analyzed
as means and 95% conﬁdence intervals, but p-values were pro-
duced using a Wilcoxon Rank Sum Test for non-normally distrib-
uted data. Categorical variables were analyzed using a Fisher’s
Exact Test.
Discussion
In MM patients with comparable pretransplant performance sta-
tus being equal, there were no statistical differences in CD34 yield,
cell viability, days of apheresis, platelet transfusions, engraftment,
complications, or mobilization regimen between those receiving
VAD and those receiving Thal Dex. However, patients receiving
Thal Dex appeared to require more RBC blood product support
(p0.03).
Results
Variables/Drug
Group Thal Dex (N11) VAD (N38) p-value
Age (years) 59.8 {53.6, 66.0} 56.5 {52.9, 60.2} 0.38
Days of
apheresis 2.18 {1.46, 2.91} 2.00 {1.68, 2.32} 0.60
CD 34 yield 7.95 {4.05, 11.8} 7.82 {6.34, 9.30} 0.74
Viability Day 1 84.3 {76.8, 91.8} 80.6 {73.2, 88.0} 0.63
Viability Day 2 85.0 {78.3, 91.7} 90.8 {88.1, 93.5} 0.06
Viability Day 3 82.4 {71.8, 93.0} 84.0 {74.7, 93.3} 0.83
Days to ANC
Engraftment 14.1 {13.3, 14.9} 13.7 {13.1, 14.2} 0.36
Days to PLT
Engraftment 18.5 {15.9, 21.2} 19.8 {17.3, 22.3} 0.82
Number of PLT
Transfusions 3.91 {1.61, 6.21} 3.74 {2.61, 4.87} 0.84
Number of RBC
Transfusions 4.54 {3.00, 6.09} 3.00 {2.39, 3.61} 0.03
Mobilization
Regimen (%G) 100 76 0.10
Death <100
days 0 0 1.00
Mucositis II-IV
<30 days 25 13.5 0.36
Sepsis <30 days 16.7 2.7 0.12
Pneumonia <30
days 8.3 2.7 0.40
Karnofsky Score 95.83 94.48 1.00
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR PATIENTS
WITH MULTIPLE MYELOMA (MM): IMPACT OF THE DEGREE OF
PLASMA CELL BONE MARROW INFILTRATION ON MOBILIZATION KI-
NETIC AND TRANSPLANT OUTCOMES
Go, A.1, Gregory, S.A.1, Venugopal, P.1, Shammo, J.1, McLeod, B.1,
Fung, H.C.1 1Rush University Medical Center, Chicago, IL.
Background: The recommended treatment for younger patients
(pts) with newly diagnosed symptomatic MM is ASCT after some
form of cytoreductive therapy. One of the goals of the cytoreductive
therapy is to reduce the tumor bulk, in particular, decrease the plasma
cell bone marrow (BM) inﬁltration to less than 10-30% prior to stem
cell collection. However, the utility of this approach is controversial.
Objective: To evaluate the impact of the degree of plasma cell bone
marrow (BM) inﬁltration on mobilization kinetic and transplant out-
comes. Method: We conducted a retrospective study on all pts with
MM who underwent ASCT at our institution between 1/99 and
12/03. Stem Cell mobilization regimen consisted of the combination
of Cyclophosphomide 1.5-3g/m2, GM-CSF (5mcg/kg) starting on
Day #3 and G-CSF (5mcg/kg) on Day#7 until targeted CD 34 count
achieved. The median age at ASCT was 55 (range 41-73). All pts
received melphalan 200mg/m2 as conditioning regimen. The pts were
grouped according to degree of plasma cell inﬁltration on BM biopsy
performed beforemobilization. Group 1 had plasma cell inﬁltration of
10% (n26), group 2 had 10-29% involvement (n27) and group
3 had 30% plasma cell inﬁltration (n16). Results: Sixty-nine
patients were included in the study; 43 were rapid mobilizers (4
106 CD34 cells/Kg in one single collection), 7 slow mobilizers
(1.5  106 CD34 cells/kg over 4 collections or more) and 19
normal mobilizers (all other patients). The median days of apheresis
was 1 (range 1-6). Ordinal logistic regression model identiﬁed that for
each 10 point (10%) increase in plasma cell BM inﬁltration prior to
mobilization, it is 1.27 times more likely to be in the next slower
mobilization group (p value 0.0449). Age did not inﬂuence the
mobilization kinetic. The median progression-free survival and over-
all survival for the entire cohort were 28.5 and 45months respectively.
There was no relationship found between plasma cell involvement
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